BotrytisAlert harnesses Mologic’s expert lateral flow technology to enable earlier disease intervention and prevent wide-spread crop failures Developed with funding from Innovate UK as part of the Company’s wider crop protection diagnostic portfolio Bedfordshire, UK, 8th October 2020: Mologic Ltd, a leading developer of lateral flow and rapid [...]
Mark Davis, CEO, Mologic: “Our involvement in Heathrow Airport’s trial for rapid point of care COVID-19 testing solutions is an exciting, and necessary, step towards getting the UK safely travelling again. As experts in lateral flow technology, our Antigen Test is designed to provide results in 10 minutes, supporting [...]
Mologic is pleased to announce that, following successful independent validation by the Liverpool School of Tropical Medicine (LSTM) and St George’s, University of London, our professional-use rapid diagnostic test for COVID-19 has been certified with a CE mark and is ready for manufacture and global distribution. The “triple antibody” [...]
BioSure joins forces with Mologic on production of COVID-19 Antibody self-test Innovative design suitable for at home, self-test giving result in 10 minutes Final validations underway ahead of mass production UK, 11 May 2020: Mologic Ltd, a leading developer of diagnostic technologies, have announced today [...]
Mologic is pleased to announce that following rigorous independent assessment by St George’s, University London and Liverpool School of Tropical Medicine, our point-of-need, professional use, rapid diagnostic test (RDT) for COVID-19 has achieved preliminary clinical performance data of 98% sensitivity at days 14-21 and specificity of 96%. The test [...]
Construction has begun on a new diagnostic manufacturing site, which will have capacity to produce up to 40 million tests per year The first products to be manufactured will be rapid COVID-19 diagnostic tests The new facility is a legally separate social enterprise with a mission to deliver diagnostics [...]
Follows successful validation by Liverpool School of Tropical Medicine and St George’s, University of London With manufacturing support from Omega Diagnostics, the laboratory-based test aims to deliver up to 46,000 results per day Health services and key worker communities in the UK and Africa will be prioritised for [...]
We are pleased to announce that Mologic’s COVID-19 laboratory and point of need antibody tests have both graduated from research and development, achieved design freeze and are ready for manufacture. Both COVID-19 tests have been independently assessed by the Liverpool School of Tropical Medicine (LSTM) and St George’s University [...]
Independent assessment and validation of COVID-19 diagnostic test has been initiated this week with the Liverpool School of Tropical Medicine and St George’s, University of London Prototypes will be sent to world-leading labs in UK, Senegal, Spain, China, Malaysia and Brazil for priority validation COVID-19 tests will be jointly [...]
Grant awarded as part of UK government’s £46 million international COVID-19 prevention and research package Test will support global efforts to prevent further spread of COVID-19 by enabling rapid diagnosis at the point-of-need Funding will also initiate Mologic’s research for novel vaccine candidates Bedfordshire, UK, 6th March 2020: Mologic [...]
Project aims to facilitate early diagnosis and support efforts to stop the Ebola Virus Disease epidemic Rapid point-of-need test critical to boosting surveillance and response to global viral outbreaks Partnership builds on BIOASTER’s early R&D during the 2014-2016 Ebola outbreak Bedfordshire, UK, 25 February 2020: Mologic Ltd, a [...]
BIOASTER receives $885K grant from the Bill & Melinda Gates Foundation to develop Onchocerciasis advanced rapid diagnostic with Mologic Ltd Lyon, January 07th, 2020 BIOASTER, the French Technology Research Institute for Microbiology and Infectious Diseases, today announced it has received a grant in the field of diagnosis of Neglected [...]